Skip to content

Evaluation of the modern indocyanine green dye in the breast cancer scenario

Evaluation of the efficacy of using indocyanine green associated with fluorescence in sentinel lymph node biopsy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6d36dgq
Enrollment
Unknown
Registered
2022-08-17
Start date
2019-08-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

986 / 5.000 Resultados de tradução star_border Patients with previously clinically negative axillary breast cancer underwent sentinel lymph node biopsy using one of 3 sentinel lymph node techniques de
patient 34 to 66 underwent indocyanine green and finally patients 67 to 99 were submitted to the combined method (patent blue + indocyanine green). There was no masking. The sentinel lymph node identi
E04.074.580
D03.633.100.473.400

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Hospital Regional do Câncer de Presidente Prudente
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Clinically negative axillary breast cancer; present surgical indication

Exclusion criteria

Exclusion criteria: T4 (chest wall or skin involvement or inflammatory); N1 (single lymph node affected); N2 (conglomerate of affected lymph nodes; N3 (supra or infraclavicular lymph node involvement; Having undergone neoadjuvant chemotherapy

Design outcomes

Primary

MeasureTime frame
Expected outcome 1 It is expected to find a high rate of sentinel lymph node identification through fluorescence;Endpoint found 1 A higher rate of sentinel lymph node detection was observed in patients undergoing the sentinel lymph node technique with the combined use of dyes (100%) compared to isolated dyes (patent blue: 78.8%, indocyanine green: 93.9%)

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactRafael da Sa

Hospital Regional do Câncer de Presidente Prudente

rafasamed@hotmail.com55(18)981514255

Outcome results

None listed

Source: REBEC (via WHO ICTRP)